WHO Addresses Planned Hepatitis B Birth Dose Vaccine Trial in Guinea-Bissau

Why Is the Hepatitis B Birth Dose Vaccine So Critical for Newborns?

Hepatitis B virus (HBV) infection acquired at birth or in early childhood carries a dramatically higher risk of becoming chronic compared with infection acquired in adulthood. According to WHO estimates, infants infected perinatally have a roughly 90% chance of developing chronic hepatitis B, which can lead to cirrhosis and hepatocellular carcinoma decades later. The hepatitis B birth dose vaccine, given within the first 24 hours of life, is the single most effective intervention to interrupt this transmission chain.

Despite the strength of the evidence, birth dose coverage remains alarmingly low across much of sub-Saharan Africa. WHO data indicates that while global birth dose coverage has risen to approximately 45%, many African countries have coverage rates well below 20%. Guinea-Bissau, a small West African nation with limited healthcare infrastructure and a high burden of hepatitis B, represents a setting where generating local trial data could help accelerate adoption and inform delivery strategies tailored to resource-constrained environments.

What Does the Planned Trial in Guinea-Bissau Involve?

The WHO statement addresses a planned randomized trial that would assess hepatitis B birth dose vaccination strategies in Guinea-Bissau. A key challenge in this region is that a significant proportion of births occur at home or in facilities with limited cold chain capacity, making timely vaccine administration within 24 hours logistically difficult. The trial is expected to evaluate delivery approaches that could overcome these barriers, potentially including outreach strategies and heat-stable vaccine formulations.

WHO has emphasized that the trial aligns with its broader Global Health Sector Strategy on Viral Hepatitis, which targets elimination of hepatitis B as a public health threat by 2030. The organization notes that generating context-specific evidence from West Africa is essential, as most existing birth dose data comes from East Asian and Pacific regions where the epidemiology and health system infrastructure differ substantially. WHO has also underscored the importance of rigorous ethical oversight and community engagement in the trial design.

What Are the Broader Implications for Global Hepatitis B Elimination?

The WHO 2030 elimination targets require that hepatitis B birth dose coverage reach at least 90% globally and that new chronic infections among children be reduced by 90% compared to 2015 levels. According to the WHO Global Hepatitis Report, the African region carries approximately 26% of the global hepatitis B burden but has the lowest birth dose coverage of any WHO region. Without rapid scale-up of birth dose vaccination in Africa, the 2030 targets are unlikely to be met.

The planned Guinea-Bissau trial could generate evidence that catalyzes policy changes across the region. Several African countries have recently introduced or are considering introducing the birth dose into their national immunization programs, and real-world data on feasibility, safety, and effectiveness from a West African setting would strengthen the case for investment. Furthermore, new vaccine delivery technologies — including compact, prefilled auto-disable devices and thermostable formulations — could transform what is possible in settings without reliable cold chains, potentially making universal birth dose coverage an achievable goal even in the most resource-limited environments.